Enveric Biosciences, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Enveric is a pre-revenue biotechnology company developing psychedelic-inspired therapeutics, including lead candidate EB-373 for anxiety disorders. Its programs remain in development; the filing reports no product revenue.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Operating expenses | $3.45 million | $5.66 million | $14.06 million | $15.16 million |
| Operating loss | $3.45 million | $5.66 million | $14.06 million | $15.16 million |
| Net loss | $2.82 million | $2.48 million | $13.86 million | $9.79 million |
| Net loss per share, basic and diluted | $1.30 | $1.46 | $6.62 | $8.11 |
| Operating cash used | Not separately stated | Not separately stated | $12.34 million | $13.68 million |
At September 30, cash was $4.27 million, down from $17.72 million at December 31, 2022. Working capital was $1.64 million. Current assets were $5.83 million and current liabilities were $4.18 million. Total assets were $6.62 million and shareholders’ equity was $2.44 million. The balance sheet presents no borrowings or other debt balance; current liabilities include accounts payable, accruals, warrant and investment-option liabilities.
No meaningful revenue margin is available because the company has not generated revenue. For the nine months, investing activities provided $12,000 and financing activities used $1.16 million, principally reflecting the $1.05 million Akos preferred-stock redemption and deferred offering costs. Cash decreased by $13.46 million overall.
Changes versus comparable periods
- Q3 operating expenses fell 39% year over year, with general and administrative expense down 43% and research and development expense down 34%, reflecting cost reductions and lower payroll, consulting, transaction, insurance and marketing costs.
- Despite lower Q3 operating expenses, quarterly net loss increased to $2.82 million from $2.48 million. Other income fell substantially, including lower gains from remeasurement of warrant and investment-option liabilities.
- Nine-month operating expenses decreased 7%, but net loss increased to $13.86 million from $9.79 million. The prior-year period included larger noncash gains from changes in fair value of warrants and investment options.
- Operating cash use improved to $12.34 million from $13.68 million for the first nine months of 2022. The company nevertheless ended September with significantly less cash, reflecting the absence of comparable financing proceeds and the Akos redemption.
Outlook, risks and unusual items
- Going concern: Management states that available cash is insufficient for the next 12 months and that substantial doubt exists about the company’s ability to continue as a going concern. It plans to reduce spending, manage cash, advance programs and seek additional financing or collaborations. Financing may not be available on acceptable terms, or at all; further cuts, delays or discontinuation of activities may be necessary.
- Development plans: EB-373 is in preclinical development, with a planned Australian Phase 1 multi-cohort, dose-ascending study to assess safety and tolerability. The Avance Clinical contract is approximately A$3.0 million (about US$2.0 million); the filing gives no clear clinical-trial start date or formal financial guidance.
- Cost reduction: A May 2023 plan reduced the workforce by approximately 35% and ended seven consultant contracts focused on the Akos spin-off. The filing reports approximately $1.00 million in restructuring costs through September 30, of which $396,000 had been paid and $608,000 remained accrued; it separately reports approximately $453,000 in severance charges.
- Financing and dilution: The September Canaccord at-the-market agreement permitted sales of up to approximately $2.39 million under the applicable offering limitations; no shares had been sold under it by September 30. A November 3, 2023 Lincoln Park agreement provides for potential purchases of up to $10 million, subject to conditions and limitations, including registration effectiveness. Any sales could dilute existing shareholders. Common shares outstanding were 2,181,912 at September 30 and 2,321,315 as of November 9.
- Akos redemption: Enveric paid approximately $1.05 million in May 2023 to redeem Akos Series A preferred stock after holders exercised a put right. The planned Akos spin-off was not completed; the company said it would seek alternative ways to capture value from cannabinoid assets.
- Controls and other risks: Disclosure controls were deemed ineffective at September 30 because material weaknesses in internal control over financial reporting continued, including inadequate segregation of duties. The company also cites early-stage development, regulatory and trial uncertainty, funding needs, competition, intellectual-property protection, foreign-exchange exposure and inflation-related cost pressures.
- Noncash valuation effects: Warrant, investment-option and derivative liabilities are Level 3 fair-value measurements requiring significant judgment. Changes in those valuations materially affected reported quarterly and year-to-date net loss.
Important facts for investors to verify
- Cash runway, actual monthly spending and whether additional capital can be raised before funds are exhausted.
- Terms, registration status, potential share issuance and realized proceeds under the Canaccord and Lincoln Park financing arrangements.
- EB-373 trial readiness, regulatory progress in Australia, expected study timing and remaining contractual cash commitments.
- Progress in remediating internal-control material weaknesses and whether disclosure controls become effective.
- Current status and value-realization plans for the cannabinoid assets following the Akos redemption and abandoned spin-off path.
- Potential dilution from outstanding warrants, investment options, restricted stock units and the amended incentive plan.